In particular, there should be a focus towards dacarbazine, the standard single-agent chemotherapy for melanoma, immunotherapies, and targeted therapies for BRAF/MEK mutations, as the latter two have emerged within the past decade as promising treatments. The gene discussed is BRAF; the disease is melanoma.